Mitral regurgitation natural history: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(23 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link=Mitral regurgitation resident survival guide]]|| <br> || <br>
| [[Mitral regurgitation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
{{Mitral regurgitation}}
{{Mitral regurgitation}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S.; [[User:Mohammed Sbeih|Mohammed A. Sbeih, M.D.]] [mailto:msbeih@perfuse.org]
{{CMG}}; {{AE}} {{CZ}}; [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S.; [[User:Mohammed Sbeih|Mohammed A. Sbeih, M.D.]] [mailto:msbeih@wikidoc.org]


==Overview==
==Overview==
The natural history of mitral regurgitaiton is divided into three phases: The acute, chronic compensated, and chronic decompensated pahses. In the acute phase, the volume and pressure overload in the left atrium is transmitted backward into the pulmonary vasculature to cause an elevation of the [[pulomanry capillary wedge pressure]] which causes [[dyspnea]], [[PND]], [[orthopnea]] and [[rales]].  During the chronic compensated phase of mitral regurgitation, the left ventricle maintains forward [[cardiac output]] by filling with a larger volume of blood than usual to accomodate the fact that a portion of the blood will go backwards into the left atrium.  In the decompensated phase, the left ventricle begins to dilate and fail. The markers of decompensation are as follows:
The natural history of mitral regurgitation (MR) may follow one of two patterns, acute or chronic. Chronic MR can be either compensated or decompensated. The natural history and prognosis of MR depend on the underlying etiology and the degree of severity of the valvular abnormality.  Mild MR is associated with few if any complications. However, when severe, MR may lead to development of [[pulmonary edema]], [[pulmonary hypertension]], and [[right heart failure]].
==Natural History==
The natural history of MR may follow one of two patterns, acute or chronic. In acute MR, the volume and pressure overload in the left atrium is transmitted backward into the pulmonary vasculature leading to sudden onset of [[dyspnea]], [[PND]], [[orthopnea]] and [[rales]].  Chronic MR can be either compensated or decompensated. During the chronic compensated phase of MR, compensatory changes in the [[left ventricle]] and [[left atrium]] maintain the forward cardiac output of the left ventricle, and minimize the signs and symptoms of pulmonary congestion that occur in the acute phase of the disease.  Individuals in the chronic compensated phase may be asymptomatic and have normal exercise tolerance.  An individual may remain in the compensated phase of mitral regurgitation for years, but will eventually develop left ventricular dysfunction, the hallmark for the chronic decompensated phase of mitral regurgitation.  Once the patient transitions into the decompensated phase, there may not be recovery of left ventricular funtion following operative repair or replacement of the [[mitral valve]]. The decompensated stage is defined on the basis of a decompensated ventricular function. At this stage, the patients are at risk for a poor results of valve replacement.


# '''Left ventricular end-diastolic dimension greater than 70 mm'''
==Complications==
# '''Left ventricular end-systolic dimension greater than 45 to 47 mm'''
Mild MR is associated with few if any complications. However, when severe, MR may lead to development of (in alphabetical order):
# '''Left ventricular [[ejection fraction]] (LVEF) less than 50 to 55 percent'''
*[[Atrial fibrillation]]
 
*[[Cardiogenic Shock]]
==Natural History Mitral Regurgitation==
*[[Endocarditis]]
The pathophysiology of chronic mitral regurgitation can be divided into '''three phases''':
*[[Pulmonary edema]]
#Acute mitral regurgitation
*[[Pulmonary hypertension]]
#Chronic compensated mitral regurgitation
*[[Right heart failure]]
#Chronic decompensated mitral regurgitation
*[[Thromboembolism]]-[[Stroke]]
 
It is helpful to classify the stage of the patient's disease so as to recognize signs that may indicate that the patient is transitioning into the decompensated phase of the disease.  '''''The goal is to perform mitral valve surgery before the patient transitions into the decompensated phase.'''''  Once the patient transitions into the decompensated phase, (left ventricular enlargement and a low [[left ventricular ejection fraction]]) there may not be recovery of left ventricular funtion following operative repair or replacement of the [[mitral valve]].
 
===Acute Phase===
*Acute mitral regurgitation (as may occur due to the sudden rupture of a [[chordae tendineae]] or [[papillary muscle]]) causes a sudden volume overload of both the [[left atrium]] and the [[left ventricle]]. 
*The left ventricle develops volume overload because with every contraction it now has to pump out not only the volume of blood that goes into the [[aorta]] (the forward [[cardiac output]] or forward [[stroke volume]]), but also the additional blood that regurgitated into the [[left atrium]] (the regurgitant volume).
*The combination of the forward stroke volume and the regurgitant volume is known as the total stroke volume of the [[left ventricle]].
*In the acute setting, the total stroke volume (i.e. the forward plus the regurgitant volume) is increased, but the forward cardiac output into the aorta is decreased because a proportion of the blood is going backward into the left atrium.  The mechanism by which the total stroke volume is increased as a result of increased left ventricular filling is known as the [[Frank-Starling law of the heart|Frank-Starling mechanism]].
 
The regurgitant volume causes acute volume overload and pressure overload of the [[left atrium]] as shown in the figure below.  The sudden increase in pressure in the [[left atrium]] is transmitted backward into the [[pulmonary vein]] which in turn reduces drainage of blood from the lungs via the [[pulmonary vein]]s and raises the [[pulmonary capillary sedge pressure]].  This causes [[congestive heart failure|pulmonary congestion]].
 
[[Image:MR pressure graph.jpg]]
 
The symptoms of an acutely elevated wedge pressure include [[dyspnea]], [[PND]], and [[orthopnea]]. On physical examination, [[rales]] may be present.
 
===Chronic Compensated Phase===
*If the mitral regurgitation develops slowly over months to years or if the acute phase is successfully managed with medical therapy, the patient enters the chronic compensated phase of mitral regurgitation.
*In this phase, the left ventricle develops eccentric hypertrophy to reduce the wall stress associated with the rise in total [[stroke volume]].
*The eccentric hypertrophy and the increased diastolic volume combine to increase the total stroke volume to levels well above normal, so that the forward stroke volume (forward cardiac output) is maintained.
*In the left atrium, the chronic volume overload causes left atrial enlargement, allowing the filling pressure in the left atrium to decrease.  This dilation of the left atrium reduces the [[pulmonary capillary wedge pressure]], and is associated with an improvement in the signs (e.e. [[rales]]) and symptoms ([[dyspnea]], [[PND]], and [[orthopnea]]) of pulmonary congestion.
*These compensatory changes in the left ventricle and left atrium maintain the forward cardiac output  of the left ventricle, and minimize the signs and symptoms of pulmonary congestion that occur in the acute phase of the disease.  Individuals in the chronic compensated phase may be asymptomatic and have normal exercise tolerance.
*In the compensated stage; the left ventricular (LV) end-diastolic dimension is less than 60 mm, and the end-systolic dimension is less than 40 mm on echocardiography.
 
===Chronic Decompensated Phase===
* An individual may remain in the compensated phase of mitral regurgitation for years, but will eventually develop left ventricular dysfunction, the hallmark for the chronic decompensated phase of mitral regurgitation. It is currently unclear what causes an individual to enter the decompensated phase of this disease.  However, the decompensated phase is characterized by calcium overload within the cardiac [[myocyte]]s.
* In this phase, the ventricular myocardium is no longer able to contract adequately to compensate for the volume overload of mitral regurgitation, and the [[stroke volume]] of the left ventricle begins to decrease.
* The reduced [[stroke volume]] causes a decrease in the forward [[cardiac output]] and an increase in the [[systole|end-systolic]] volume.
* The increased left ventricular end-systolic volume in turn causes increased [[left ventricular end diastolic pressures]] and increased [[pulmonary capillary wedge pressures]].
* As the wedge pressure rises, the patient may develop symptoms of [[congestive heart failure]] such as [[dyspnea]], [[PND]] and [[orthopnea]] and signs of congestive heart failure including [[rales]].
* With the rise in wall stress that accompanies the rise in pressure and volume in the left ventricle, the left ventricle begins to dilate during this phase.  This causes a dilatation of the [[mitral valve annulus]], which may further worsen the degree of mitral regurgitation.
* While the [[ejection fraction]] is less in the chronic decompensated phase than in the acute phase or the chronic compensated phase of mitral regurgitation, it may still be in the normal range (i.e: > 50 percent), and may not decrease until late in the disease course. A decreased ejection fraction in an individual with mitral regurgitation and no other cardiac abnormality should alert the physician that the disease may be in its decompensated phase.
* The decompensated stage defined on the basis of decompensated ventricular function. At this stage; the patients are at risk for a poor results of valve replacement.
 
====Markers of Decompensated Ventricular Function in Mitral Regurgitaiton====
# '''Left ventricular end-diastolic dimension greater than 70 mm'''
# '''Left ventricular end-systolic dimension greater than 45 to 47 mm'''
# '''Left ventricular [[ejection fraction]] (LVEF) less than 50 to 55 percent'''
 
==Complications of Mitral Regurgitation==
Mitral Regurgitation when mild almost never cause any complications. However, when severe, it may lead to development of:
*[[Pulmonary Edema]].
*[[Pulmonary Hypertension]].
*[[Right Heart Failure]].
*[[Atrial Fibrillation]].
*[[Thromboembolism]]-[[Stroke]].
*[[Endocarditis]].


==Prognosis==
==Prognosis==
*Patients with asymptomatic chronic severe [[mitral regurgitation]] have a high likelihood of developing symptoms or LV dysfunction over the course of 6 to 10 years <ref name="pmid8875918">{{cite journal |author=Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL |title=Clinical outcome of mitral regurgitation due to flail leaflet |journal=[[The New England Journal of Medicine]] |volume=335 |issue=19 |pages=1417–23 |year=1996 |month=November |pmid=8875918 |doi=10.1056/NEJM199611073351902|url=http://dx.doi.org/10.1056/NEJM199611073351902 |accessdate=2011-03-06}}</ref> <ref name="pmid15745978">{{cite journal |author=Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ |title=Quantitative determinants of the outcome of asymptomatic mitral regurgitation |journal=[[The New England Journal of Medicine]] |volume=352 |issue=9 |pages=875–83 |year=2005 |month=March |pmid=15745978 |doi=10.1056/NEJMoa041451 |url=http://dx.doi.org/10.1056/NEJMoa041451|accessdate=2011-03-06}}</ref> <ref name="pmid16651470">{{cite journal |author=Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H|title=Outcome of watchful waiting in asymptomatic severe mitral regurgitation |journal=[[Circulation]] |volume=113 |issue=18 |pages=2238–44 |year=2006 |month=May |pmid=16651470|doi=10.1161/CIRCULATIONAHA.105.599175 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16651470 |accessdate=2011-03-06}}</ref>. However, the incidence of [[sudden death]] in asymptomatic patients with normal LV function varies widely among these studies.
Patients with asymptomatic chronic severe MR have a high likelihood of developing symptoms or [[left ventricular dysfunction]] over the course of 6 to 10 years.<ref name="pmid8875918">{{cite journal |author=Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL |title=Clinical outcome of mitral regurgitation due to flail leaflet |journal=[[The New England Journal of Medicine]] |volume=335 |issue=19 |pages=1417–23 |year=1996 |month=November |pmid=8875918 |doi=10.1056/NEJM199611073351902|url=http://dx.doi.org/10.1056/NEJM199611073351902 |accessdate=2011-03-06}}</ref><ref name="pmid15745978">{{cite journal |author=Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ |title=Quantitative determinants of the outcome of asymptomatic mitral regurgitation |journal=[[The New England Journal of Medicine]] |volume=352 |issue=9 |pages=875–83 |year=2005 |month=March |pmid=15745978 |doi=10.1056/NEJMoa041451 |url=http://dx.doi.org/10.1056/NEJMoa041451|accessdate=2011-03-06}}</ref><ref name="pmid16651470">{{cite journal |author=Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H|title=Outcome of watchful waiting in asymptomatic severe mitral regurgitation |journal=[[Circulation]] |volume=113 |issue=18 |pages=2238–44 |year=2006 |month=May |pmid=16651470|doi=10.1161/CIRCULATIONAHA.105.599175 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16651470 |accessdate=2011-03-06}}</ref> The incidence of [[sudden death]] in asymptomatic patients with normal [[left ventricular]] function varies widely among studies.


*Clinical outcome is poor in patients with severe symptomatic [[mitral regurgitation]] with eight year survival rate of 33% without surgical intervention. [[Heart failure]] being the common cause with [[sudden death]] attributing to ventricular arrhythmia <ref name="pmid1936025">{{cite journal |author=Delahaye JP, Gare JP, Viguier E, Delahaye F, De Gevigney G, Milon H |title=Natural history of severe mitral regurgitation |journal=[[European Heart Journal]] |volume=12 Suppl B |issue= |pages=5–9 |year=1991 |month=July |pmid=1936025 |doi=|url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=1936025 |accessdate=2011-03-06}}</ref>.
The prognosis is poor in patients with severe symptomatic MR with an estimated eight year survival rate of only 33% in the absence of surgical intervention. [[Heart failure]] and [[sudden death]] due to ventricular arrhythmia are common causes of death.<ref name="pmid1936025">{{cite journal |author=Delahaye JP, Gare JP, Viguier E, Delahaye F, De Gevigney G, Milon H |title=Natural history of severe mitral regurgitation |journal=[[European Heart Journal]] |volume=12 Suppl B |issue= |pages=5–9 |year=1991 |month=July |pmid=1936025 |doi=|url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=1936025 |accessdate=2011-03-06}}</ref>


*In patients with severe mitral regurgitation due to a flail [[posterior mitral leaflet]], 90% of patients are dead or require MV operation at 10 years with the mortality rate in patients with severe mitral regurgitation being 6% to 7% per year. However, the risk of death are predominantly in patients with a left ventricular ejection fraction <60% or with NYHA functional class III–IV symptoms <ref name="pmid8875918">{{cite journal |author=Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL |title=Clinical outcome of mitral regurgitation due to flail leaflet |journal=[[The New England Journal of Medicine]] |volume=335 |issue=19 |pages=1417–23 |year=1996 |month=November |pmid=8875918|doi=10.1056/NEJM199611073351902 |url=http://dx.doi.org/10.1056/NEJM199611073351902 |accessdate=2011-03-06}}</ref> <ref name="pmid9918527">{{cite journal |author=Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL |title=Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications |journal=[[Circulation]] |volume=99 |issue=3 |pages=400–5 |year=1999 |month=January |pmid=9918527 |doi=|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9918527 |accessdate=2011-03-06}}</ref>.
Among subjects with severe MR due to a flail posterior mitral leaflet, 90% of patients are either dead or require mitral valve surgery by 10 years with a mortality rate of 6% to 7% per year. However, the risk of death is higher in those patients with a [[left ventricular ejection fraction]] <60% or with [[NYHA]] functional class III–IV symptoms.<ref name="pmid8875918">{{cite journal |author=Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL |title=Clinical outcome of mitral regurgitation due to flail leaflet |journal=[[The New England Journal of Medicine]] |volume=335 |issue=19 |pages=1417–23 |year=1996 |month=November |pmid=8875918|doi=10.1056/NEJM199611073351902 |url=http://dx.doi.org/10.1056/NEJM199611073351902 |accessdate=2011-03-06}}</ref><ref name="pmid9918527">{{cite journal |author=Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL |title=Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications |journal=[[Circulation]] |volume=99 |issue=3 |pages=400–5 |year=1999 |month=January |pmid=9918527 |doi=|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9918527 |accessdate=2011-03-06}}</ref>


*Severe symptoms also predict a poor outcome after mitral valve repair or replacement. Postoperative survival rates in patients with NYHA functional class III–IV symptoms at 5 and 10 years are 73 ± 3% and 48 ± 4%, respectively. While in patients with NYHA functional class I/II symptoms before surgery survival rates at 5 and 10 years are 90 ± 2% and 76 ± 5%, respectively <ref name="pmid9918527">{{cite journal |author=Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL |title=Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications |journal=[[Circulation]] |volume=99 |issue=3|pages=400–5 |year=1999 |month=January |pmid=9918527 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9918527 |accessdate=2011-03-06}}</ref>.
Severe symptoms are associated with a poor outcome after [[mitral valve]] repair or replacement. Postoperative survival rates in patients with NYHA functional class III–IV symptoms at 5 and 10 years are 73 ± 3% and 48 ± 4% respectively, compared to 5 and 10 years survival rates of 90 ± 2% and 76 ± 5% respectively among patients with NYHA functional class I/II symptoms before surgery.<ref name="pmid9918527">{{cite journal |author=Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL |title=Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications |journal=[[Circulation]] |volume=99 |issue=3|pages=400–5 |year=1999 |month=January |pmid=9918527 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=9918527 |accessdate=2011-03-06}}</ref>


*In a long-term retrospective study <ref name="pmid15745978">{{cite journal |author=Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ |title=Quantitative determinants of the outcome of asymptomatic mitral regurgitation |journal=[[The New England Journal of Medicine]] |volume=352 |issue=9 |pages=875–83|year=2005 |month=March |pmid=15745978 |doi=10.1056/NEJMoa041451 |url=http://dx.doi.org/10.1056/NEJMoa041451 |accessdate=2011-03-06}}</ref>, 198 patients with an effective orifice area >40 mm² had a risk of cardiac death at 4% per year during a mean follow-up period of 2.7 years. However, in the another study where 132 patients were followed up prospectively for 5 years, indications for surgery were development of symptoms, LV dysfunction ([[EF]] <60%), LV dilatation (LV end-systolic diameter >45 mm), [[atrial fibrillation]], or [[pulmonary hypertension]] and there was only 1 cardiac death in an asymptomatic patient, but this patient had refused surgery though it was indicated by development of LV dilation <ref name="pmid16651470">{{cite journal |author=Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H |title=Outcome of watchful waiting in asymptomatic severe mitral regurgitation |journal=[[Circulation]] |volume=113 |issue=18 |pages=2238–44 |year=2006 |month=May |pmid=16651470 |doi=10.1161/CIRCULATIONAHA.105.599175|url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16651470 |accessdate=2011-03-06}}</ref>. This suggests good prognosis with valve surgery.
In a long-term retrospective study, 198 patients with an effective orifice area >40 mm² had a risk of cardiac death of 4% per year during a mean follow-up period of 2.7 years.<ref name="pmid15745978">{{cite journal |author=Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ |title=Quantitative determinants of the outcome of asymptomatic mitral regurgitation |journal=[[The New England Journal of Medicine]] |volume=352 |issue=9 |pages=875–83|year=2005 |month=March |pmid=15745978 |doi=10.1056/NEJMoa041451 |url=http://dx.doi.org/10.1056/NEJMoa041451 |accessdate=2011-03-06}}</ref>


*In 80% of patients with [[atrial fibrillation]] greater than or equal to 3 months duration during the pre-operative period had persistence of [[atrial fibrillation]] after surgery. Hence, mitral valve repair should be done before or soon after the onset of atrial fibrillation to maximize the chance of postoperative sinus rhythm and avoid long-term anticoagulation with warfarin <ref name="pmid8302059">{{cite journal |author=Chua YL, Schaff HV, Orszulak TA, Morris JJ |title=Outcome of mitral valve repair in patients with preoperative atrial fibrillation. Should the maze procedure be combined with mitral valvuloplasty? |journal=[[The Journal of Thoracic and Cardiovascular Surgery]] |volume=107|issue=2 |pages=408–15 |year=1994 |month=February |pmid=8302059 |doi= |url= |accessdate=2011-03-06}}</ref>.
Acute MR with [[cardiogenic shock]] is associated with an operative mortality of 80%.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
 
{{WS}}
[[Category:Needs overview]]


[[Category:Valvular heart disease]]
[[Category:Valvular heart disease]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Cardiac surgery]]
[[Category:Cardiac surgery]]
[[Category:Surgery]]
[[Category:Surgery]]
[[Category:Overview complete]]
[[Category:Overview complete]]
[[Category:Template complete]]
 
[[Category:Disease]]
{{WH}}
{{WS}}

Latest revision as of 18:20, 9 September 2014
Resident
Survival
Guide

Mitral Regurgitation Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Mitral Regurgitation from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Stages

History and Symptoms

Physical Examination

Chest X Ray

Electrocardiogram

Echocardiography

Cardiac MRI

Cardiac Catheterization

Treatment

Overview

Acute Mitral Regurgitation Treatment

Chronic Mitral Regurgitation Treatment

Surgery

Follow Up

Case Studies

Case #1

Mitral regurgitation natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mitral regurgitation natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onMitral regurgitation natural history

CDC on Mitral regurgitation natural history

Mitral regurgitation natural history in the news

Blogs on Mitral regurgitation natural history

Directions to Hospitals Treating Mitral regurgitation

Risk calculators and risk factors for Mitral regurgitation natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Mohammed A. Sbeih, M.D. [3]

Overview

The natural history of mitral regurgitation (MR) may follow one of two patterns, acute or chronic. Chronic MR can be either compensated or decompensated. The natural history and prognosis of MR depend on the underlying etiology and the degree of severity of the valvular abnormality. Mild MR is associated with few if any complications. However, when severe, MR may lead to development of pulmonary edema, pulmonary hypertension, and right heart failure.

Natural History

The natural history of MR may follow one of two patterns, acute or chronic. In acute MR, the volume and pressure overload in the left atrium is transmitted backward into the pulmonary vasculature leading to sudden onset of dyspnea, PND, orthopnea and rales. Chronic MR can be either compensated or decompensated. During the chronic compensated phase of MR, compensatory changes in the left ventricle and left atrium maintain the forward cardiac output of the left ventricle, and minimize the signs and symptoms of pulmonary congestion that occur in the acute phase of the disease. Individuals in the chronic compensated phase may be asymptomatic and have normal exercise tolerance. An individual may remain in the compensated phase of mitral regurgitation for years, but will eventually develop left ventricular dysfunction, the hallmark for the chronic decompensated phase of mitral regurgitation. Once the patient transitions into the decompensated phase, there may not be recovery of left ventricular funtion following operative repair or replacement of the mitral valve. The decompensated stage is defined on the basis of a decompensated ventricular function. At this stage, the patients are at risk for a poor results of valve replacement.

Complications

Mild MR is associated with few if any complications. However, when severe, MR may lead to development of (in alphabetical order):

Prognosis

Patients with asymptomatic chronic severe MR have a high likelihood of developing symptoms or left ventricular dysfunction over the course of 6 to 10 years.[1][2][3] The incidence of sudden death in asymptomatic patients with normal left ventricular function varies widely among studies.

The prognosis is poor in patients with severe symptomatic MR with an estimated eight year survival rate of only 33% in the absence of surgical intervention. Heart failure and sudden death due to ventricular arrhythmia are common causes of death.[4]

Among subjects with severe MR due to a flail posterior mitral leaflet, 90% of patients are either dead or require mitral valve surgery by 10 years with a mortality rate of 6% to 7% per year. However, the risk of death is higher in those patients with a left ventricular ejection fraction <60% or with NYHA functional class III–IV symptoms.[1][5]

Severe symptoms are associated with a poor outcome after mitral valve repair or replacement. Postoperative survival rates in patients with NYHA functional class III–IV symptoms at 5 and 10 years are 73 ± 3% and 48 ± 4% respectively, compared to 5 and 10 years survival rates of 90 ± 2% and 76 ± 5% respectively among patients with NYHA functional class I/II symptoms before surgery.[5]

In a long-term retrospective study, 198 patients with an effective orifice area >40 mm² had a risk of cardiac death of 4% per year during a mean follow-up period of 2.7 years.[2]

Acute MR with cardiogenic shock is associated with an operative mortality of 80%.

References

  1. ↑ 1.0 1.1 Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL (1996). "Clinical outcome of mitral regurgitation due to flail leaflet". The New England Journal of Medicine. 335 (19): 1417–23. doi:10.1056/NEJM199611073351902. PMID 8875918. Retrieved 2011-03-06. Unknown parameter |month= ignored (help)
  2. ↑ 2.0 2.1 Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ (2005). "Quantitative determinants of the outcome of asymptomatic mitral regurgitation". The New England Journal of Medicine. 352 (9): 875–83. doi:10.1056/NEJMoa041451. PMID 15745978. Retrieved 2011-03-06. Unknown parameter |month= ignored (help)
  3. ↑ Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H (2006). "Outcome of watchful waiting in asymptomatic severe mitral regurgitation". Circulation. 113 (18): 2238–44. doi:10.1161/CIRCULATIONAHA.105.599175. PMID 16651470. Retrieved 2011-03-06. Unknown parameter |month= ignored (help)
  4. ↑ Delahaye JP, Gare JP, Viguier E, Delahaye F, De Gevigney G, Milon H (1991). "Natural history of severe mitral regurgitation". European Heart Journal. 12 Suppl B: 5–9. PMID 1936025. Retrieved 2011-03-06. Unknown parameter |month= ignored (help)
  5. ↑ 5.0 5.1 Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL (1999). "Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications". Circulation. 99 (3): 400–5. PMID 9918527. Retrieved 2011-03-06. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mitral_regurgitation_natural_history&oldid=1019730"